Category: Latest News

From February 29th through March 2nd of this year, MS researchers and clinicians gathered in West Palm Beach for the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024. These healthcare professionals came not only to ask questions but also to provide answers obtained from recent studies addressing varied facets of multiple sclerosis.

The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as MS Awareness Month and is pleased to present the 2024 awareness campaign theme of Improving Lives Through Supportive Connections. Throughout the month of March, MSAA will provide various programs focused on the power of social interactions and connections, mental health and emotional support, as well as additional factors that assist in the empowerment and enhancement of the quality of life for individuals affected by multiple sclerosis.

The new year began with welcome news on many fronts in terms of clinicians’ enhanced ability to understand and treat multiple sclerosis (MS) and patients’ enhanced ability to improve their health. This edition of “What’s New in MS Research” highlights several of those findings. They include information on a telehealth program that drove significant weight loss in people contending with both MS and obesity, and an internet-delivered cognitive behavioral therapy intervention designed specifically for people with MS that has been shown to reduce depressive symptoms.

Milan, Italy served as the setting for cutting-edge science and high hopes last month, when multiple sclerosis (MS) researchers and clinicians from around the world gathered there in October for MSMilan2023, the 9th joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).

This edition of “What’s New in MS Research” opens with a pair of “firsts:” the first listing of multiple sclerosis (MS) therapies on the World Health Organization’s List of Essential Medicines and the first United States Food and Drug Administration (FDA) approval of a biosimilar therapy for the long-term treatment of MS.

The Multiple Sclerosis Association of America (MSAA) is proud to announce that we have received an APEX Award for Excellence from the 35th Annual APEX Awards! This award was presented for MSAA’s Winter/Spring 2022 edition of The Motivator under the Magazines, Journals & Tabloids category for print publications 32 pages and longer.

More than 1,800 multiple sclerosis (MS) researchers, clinicians, and advocates recently convened at the base of the Rocky Mountains for high-level discussions on the latest findings on the potential causes, impact, diagnosis, and management of MS.

The Multiple Sclerosis Association of America (MSAA) is pleased to announce that we are the recipients of three awards from the 2023 Digital Health Awards®! Digital Health Awards has honored the best digital health resources developed for consumers and health professionals for 25 years.

Multiple sclerosis (MS) clinicians and research were well represented when neurologists from across the country and around the world gathered in Boston in April for the 75th Annual Meeting of the American Academy of Neurology (AAN). Indeed, findings from more than 270 studies on various aspects of MS were presented at the meeting.

The Multiple Sclerosis Association of America (MSAA), the Chronic Health Improvement Research Program (CHIRP) at Dartmouth Health, and Novartis Pharmaceuticals Corporation (“Novartis”) are collaborating to launch the Multiple Sclerosis Implementation Network™ (MSIN™). This is a first-of-its-kind initiative to develop a multi-center learning health network for providers to support people living with multiple sclerosis (MS).